Clinical Insights Into Managing Heavily Pretreated HER2+  Metastatic Breast Cancer

Clinical Brief: Beyond Third-Line Therapy in HER2+ Metastatic Breast Cancer

Key Themes:

• Clinical Trial Priority: Enrollment in clinical trials is ideal for heavily pretreated patients
• Fourth-Line Options: If the HER2CLIMB regimen is used in the third line, T-DM1 becomes a preferred fourth-line option
• Personalized Selection Factors: Prior treatments, residual toxicities, and patient preferences guide therapy selection in later lines

Key Points for Physicians:

• Multiple guideline-supported options exist beyond the third line, including taxanes with trastuzumab, capecitabine with trastuzumab or lapatinib, margetuximab, and others
• Consider residual toxicities when selecting later-line therapy (eg, avoid taxanes with significant neuropathy)
• Limited clinical experience exists with sequential tyrosine kinase inhibitor (TKI) use (eg, neratinib after tucatinib)
• Novel agents in clinical trials include new antibody-drug conjugates and bispecific antibodies

Notable Insights:

• Decision-making becomes highly nuanced in later lines of therapy
• Despite multiple theoretical options, some agents such as margetuximab have limited real-world adoption
• The theoretical rationale for sequential TKI use based on specificity profiles has not been widely tested in practice

Clinical Significance:

Beyond third-line therapy for HER2+ metastatic breast cancer, treatment selection becomes increasingly individualized based on prior treatments, toxicity profiles, and patient preferences, with clinical trials offering the most promising opportunities for heavily pretreated patients.